You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

programmed cell death protein-1 inhibitor

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

Not yet recruiting
  • Recurrent ALK Positive Large B-Cell Lymphoma
  • +28 more
  • Biospecimen Collection
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 17, 2022

Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1 Trial in Beijing (Camrelizumab plus Concurrent

Recruiting
  • Cervical Carcinoma
  • +8 more
  • Camrelizumab plus Concurrent chemoradiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 5, 2022

NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Capsulized Fecal Microbiota Transplant
  • +2 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Aug 12, 2021

EBV Infection Trial in Beijing (PD1 antibody, lenalidomide)

Recruiting
  • EBV Infection
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Jan 4, 2022

Lung Cancer, Non-Small Cell Trial in Worldwide (Pembrolizumab, Dostarlimab, GSK4428859A)

Recruiting
  • Lung Cancer, Non-Small Cell
  • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  • +14 more
Dec 26, 2022

Cholangiocarcinoma, Intrahepatic Trial in Shanghai (combined therapy using oxaliplatin and gemcitabine chemo, Lenvatinib and PD1

Active, not recruiting
  • Cholangiocarcinoma, Intrahepatic
  • combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Jul 5, 2021

Advanced Solid Tumors Trial in Australia (HLX20)

Completed
  • Advanced Solid Tumors
  • Darlinghurst, New South Wales, Australia
  • +5 more
Jun 1, 2022

Oral Cancer, Induction Chemo, Programmed Cell Death 1 Inhibitor Trial in Shanghai (drug, procedure, radiation)

Active, not recruiting
  • Oral Cancer
  • +3 more
  • Shanghai, Shanghai, China
    Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong
Nov 17, 2021

Recurrent/ Advanced Stage Endometrial Cancer Patients Trial in Guangzhou (Niraparib in Combination With Anti-PD1 Antibody)

Recruiting
  • Recurrent/ Advanced Stage Endometrial Cancer Patients
  • Niraparib in Combination With Anti-PD1 Antibody
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Centre
Aug 20, 2021

Melanoma Trial in Worldwide (Relatlimab, Ipilimumab)

Active, not recruiting
  • Melanoma
  • Tucson, Arizona
  • +29 more
Dec 13, 2022

Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone Trial in Shanghai (Camrelizumab and fluzoparib with concurrent stereotactic body

Recruiting
  • Sarcoma
  • +2 more
  • Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University, School of Medici
Oct 3, 2023

Advanced or Unresectable Melanoma Progressing After PD1 Blockade Trial in Norway, United States (ONCOS-102, Cyclophosphamide,

Completed
Has Results
  • Advanced or Unresectable Melanoma Progressing After PD1 Blockade
  • ONCOS-102
  • +2 more
  • Baltimore, Maryland
  • +3 more
Oct 11, 2021

Hodgkin's Lymphoma Trial in Seattle (Pembrolizumab, Umbralisib)

Terminated
  • Hodgkin's Lymphoma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 22, 2022

Bladder Cancer Trial in Korea, Republic of, Poland, United States (PF-07225570, sasanlimab)

Recruiting
  • Bladder Cancer
  • New York, New York
  • +5 more
Jun 28, 2022

Donafenib Trial in Shanghai (Donafenib, PD-1, TACE)

Recruiting
  • Donafenib
  • Donafenib, PD-1
  • TACE
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University,
Mar 4, 2022

NSCLC Stage II, NSCLC Stage III, PET/CT Trial in ZhuHai (pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin)

Unknown status
  • Non-small Cell Lung Cancer Stage II
  • +2 more
  • pembrolizumab, pemetrexed, gemcitabine, cisplatin, carboplatin
  • ZhuHai, Guangdong, China
    the fifth affiliated hospital of Sun yat-sen university
Aug 22, 2021

NSCLC Trial in China (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)

Active, not recruiting
Has Results
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +2 more
  • Hefei, Anhui, China
  • +16 more
Oct 14, 2022

Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma Trial in New York (Nivolumab, Atezolizumab, Radiation &

Terminated
Has Results
  • Metastatic Renal Cell Carcinoma
  • Metastatic Urothelial Carcinoma
  • New York, New York
    Weill Cornell Medicine - New York Presbyterian Hospital
Aug 26, 2021

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Multiple Myeloma Trial in Belgium, Israel, Spain (Daratumumab, JNJ-63723283)

Completed
Has Results
  • Multiple Myeloma
  • Antwerpen, Belgium
  • +12 more
Dec 1, 2022

Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer Trial in Seattle (Aldesleukin,

Recruiting
  • Advanced Clear Cell Renal Cell Carcinoma
  • +3 more
  • Aldesleukin
  • Pembrolizumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 5, 2022

NSCLC Trial in Worldwide (Sacituzumab Govitecan-hziy (SG), Docetaxel)

Recruiting
  • Non-Small Cell Lung Cancer
  • Anchorage, Alaska
  • +104 more
Jul 20, 2022

Regorafenib Plus Programmed Cell Death-1 Inhibitors in Advanced

Active, not recruiting
  • Advanced Colorectal Carcinoma
  • Beijing, China
    Department of Medical Oncology, Peking Union Medical College Hos
Feb 23, 2021

Colorectal Tumors Trial in New York (Botensilimab, Balstilimab)

Not yet recruiting
  • Colorectal Neoplasms
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
Jan 24, 2023

Programmed Cell Death 1 Trial in Assiut (Thoracic Paravertebral block)

Recruiting
  • Programmed Cell Death 1
  • Thoracic Paravertebral block
  • Assiut, Egypt
    South Egypt Cancer Institute
Dec 5, 2020